ArticleCureus2022
Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isatuximab is a newly approved targeted therapy for the treatment of patients with advanced multiple myeloma. Infusion reactions happen often with targeted therapies like isatuximab and can be severe or even life-threatening. However, ocular infusion reactions are rare. We report a 75-year-old female who presented with right eye erythema and associated pain and was found to have had a rapid onset of unilateral hemorrhagic chemosis following an initial infusion of isatuximab. She developed erythema in her right eye, associated with pain, swelling, burning, and a foreign body sensation. Visual acuity in the right eye decreased to light perception only within the first few minutes. The infusion was discontinued, and the patient was treated with steroids and intraocular pressure-lowering drugs. She was monitored for 24 hours and then discharged after symptomatic improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.